MedTrace Logo

A Study to Investigate GB-0895 in Adults With Mild to Moderate Asthma or COPD

NCT07116889 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 156

Last updated 2025-11-05

No results posted yet for this study

Summary

This study is testing the safety, tolerability, pharmacokinetics and pharmacodynamics of GB-0895.

Conditions

  • Asthma
  • COPD (Chronic Obstructive Pulmonary Disease)

Interventions

BIOLOGICAL

GB-0895 (SC)

Single subcutaneous dose of GB-0895

BIOLOGICAL

GB-0895 (SC)

Multiple subcutaneous doses of GB-0895

DRUG

Placebo (SC)

Single subcutaneous dose of placebo

DRUG

Placebo (SC)

Multiple subcutaneous doses of placebo

Sponsors & Collaborators

  • Generate Biomedicines

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-12-12
Primary Completion
2027-05-31
Completion
2027-05-31
FDA Drug
Yes

Countries

  • United States
  • Germany
  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07116889 on ClinicalTrials.gov